Updated Jul 16, 2026
BENNETT C FRANK has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $19.80M.

C. Frank Bennett is an executive at Ionis Pharmaceuticals, serving as the Executive Vice President and Chief Scientific Officer. He has been involved in the development of antisense technology and has contributed to the company's drug pipeline targeting various diseases.
| Role | EVP, Chief Scientific Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-09 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 15.0K | $85.46 | $1.28M |
| 2026-07-09 | IONS | IONIS PHARMACEUTICALS INC | J — Other acquisition / disposition | 15.0K | $0.00 | |
| 2026-07-09 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 5.5K | $83.58 | $463K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 802 | $80.76 | $65K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 12.7K | $79.88 | $1.01M |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 71.6K | $79.10 | $5.66M |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 48.6K | $60.89 | $2.96M |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 16.5K | $32.60 | $537K |
| 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | J — Other acquisition / disposition | 261 | $48.87 | $13K |
| 2026-02-14 | IONS | IONIS PHARMACEUTICALS INC | J — Other acquisition / disposition | 0 | $0.00 | |
| 2026-02-04 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 16.5K | $83.03 | $1.37M |
| 2026-02-04 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 16.5K | $32.60 | $537K |
| 2026-02-04 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 48.6K | $83.03 | $4.04M |
| 2026-02-04 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 48.6K | $60.89 | $2.96M |
| 2026-02-04 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 20.0K | $82.60 | $1.65M |
| 2026-02-03 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 5.9K | $82.95 | $488K |
| 2026-02-03 | IONS | IONIS PHARMACEUTICALS INC | A — Grant or award | 11.4K | $0.00 | |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 9.0K | $75.15 | $675K |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 21.1K | $0.00 | |
| 2025-09-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 6.0K | $59.60 | $358K |
C. Frank Bennett is an executive at Ionis Pharmaceuticals, serving as the Executive Vice President and Chief Scientific Officer. He has been involved in the development of antisense technology and has contributed to the company's drug pipeline targeting various diseases.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($19.80M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live BENNETT C FRANK profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.